Acta Scientific Pharmacology (ASPC)

Conceptual Paper Volume 1 Issue 2

Vildagliptin : The Game Changer

Monika Kapoor*

Department of Pharmacy Practice, I.S.F College of Pharmacy, Moga, Punjab, India

*Corresponding Author: Monika Kapoor, Department of Pharmacy Practice, I.S.F College of Pharmacy, Moga, Punjab, India.

Received: January 02, 2019; Published: January 21, 2020

×

  Vildagliptin is a potent and selective, oral hypoglycemic agent that belongs to the class of second-generation dipeptidyl peptidase IV inhibitors (DPP-IV) also known as “incretin enhancers”. The European Medicines Agency (EMEA) has given approval for the use of vildagliptin in combination with other hypoglycemic agents including metformin, sulfonylureas, insulin, pioglitazone and thiazolidinediones. Apart from this Eucreas, which is a single tablet formulation of metformin and vildagliptin has also been approved. The drug seems to include disease-modifying effects on patients with type2 diabetes. Vildagliptin treatment is known for neutral weight and lipid-neutral effects, very low risk of edema and low blood sugar. Moreover, it has been indicated to improve cardiovascular disease in patients with type 2 DM in multiple monotherapies and in combination.

×

References

×

Citation

Citation: Monika Kapoor. “Vildagliptin : The Game Changer”. Acta Scientific Paediatrics 1.2 (2020): 02.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US